A clinical trial investigating tazemetostat, an EZH2 methyltransferase inhibitor, was recently initiated in patients with R/M, PD-L1-positive HNSCC that have progressed on PD(L)-1 checkpoint blockade. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.